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NSABP = National Surgical Adjuvant Breast and Bowel Project
AC = doxorubicin, cyclophosphamide; CAF = cyclophosphamide, doxorubicin, 5-fluorouracil; CMF = cyclophosphamide, methotrexate, 5-fluo-
rouracil; ER = estrogen receptor; FISH = fluorescence in situ hybridization; PCNA = proliferating cell nuclear antigen; PR = progesterone receptor;
VEGF = vascular endothelial growth factor.
Available online http://breast-cancer-research.com/content/3/6/361
Introduction
The definition of accurate markers in response to adjuvant
chemotherapy to select the appropriate adjuvant therapy
would immensely improve efficacy and would avoid unnec-
essary toxicity and long-term sequelae in those patients
not responsive to the selected adjuvant chemotherapy.
So far, the strongest predictive and prognostic factor has
been the number of affected lymph nodes. However, the
clinical outcome remains unpredictable in spite of effective
adjuvant therapy. Many investigators have therefore focused
on finding molecular markers that may predict prognosis
and response to therapy. When evaluating a molecular
marker as a predicting factor, two aspects have to be taken
into account. One is the likelihood of response to agents
that target and modulate this particular marker, the other is
the accuracy with which its absence or presence predicts
for response to current standard therapy. It is well estab-
lished that the expression of the estrogen receptor (ER) or
the progesterone receptor (PR) determines the responsive-
ness of tumors to hormonal interventions; nevertheless the
absence or presence of these hormone receptors does not
predict the response to chemotherapy.
Of the many molecular markers that have been studied,
we shall focus on HER-2/neu (HER2, c-erbB2, p185),
p53 and Bcl-2. Others markers of interest are cathepsin
B, Retinoblastoma, p27, proliferating cell nuclear antigen
(PCNA), cyclin D, Ki-67, and vascular endothelial growth
factor (VEGF). Although their role as prognostic factors is
being evaluated, very little is known about their predictive
value.
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C-erbB2/HER-2/neu
One of the most interesting molecular markers currently
being studied is HER-2/neu. The neu proto-oncogene
encodes a receptor tyrosine kinase of the HER kinase
family. Amplification and overexpression of this oncogene
is seen in 25–30% of breast cancers and is associated
with a poor prognosis [1]; however, this is limited to node-
positive disease. The level of gene amplification or expres-
sion of HER-2/neu undoubtedly determines the response
to trastuzumab (Herceptin™), a monoclonal antibody
directed against HER-2/neu receptor. Only tumors with
3+ protein expression or gene amplification are likely to
benefit from this type of therapy. However, several studies
have addressed the role of HER-2/neu in predicting the
response to chemotherapy.
In a large study performed by the National Surgical Adju-
vant Breast and Bowel Project (NSABP) (B-11), patients
with node-positive, ER-negative tumors were treated with
phenylalanine-mustard and 5-fluorouracil with or without
doxorubicin. The interaction between the overexpression of
HER-2/neu and doxorubicin was significant for disease-
free survival but not for overall survival [2]. A second study
performed by the NSABP (B-15) compared the response
to adjuvant therapy with AC (doxorubicin, cyclophos-
phamide) with that to CMF (cyclophosphamide, methotrex-
ate, 5-fluorouracil) in tumors with either high or low
expression of HER-2/neu. In this study, AC was superior
only in patients with HER-2/neu-positive tumors; however,
the analysis did not reach statistical significance [3].
A trial performed by the Cancer and Leukemia Group B
(CALGB 8541) compared three doses of doxorubicin
(high, moderate, and low) in the CAF regimen (cyclophos-
phamide, doxorubicin, 5-fluorouracil) in women with node-
positive breast cancer. Patients whose tumors showed
high expression of HER-2/neu had significantly longer
disease-free survival and overall survival when treated with
moderate or high doses of doxorubicin [4]. This study was
then re-evaluated after a longer follow-up period and with
further patients. The interaction between CAF and HER-
2/neu in the original set of patients remained significant
with a longer follow-up. However, in the group of patients
added later there was only a trend towards a benefit with
anthracycline-based therapy, but this did not reach statisti-
cal significance without adjustment for other prognostic
factors [5].
Another study presented at the American Society of Clini-
cal Oncology (ASCO) meeting in 1998 evaluated the pre-
dictive value of HER-2/neu in a subset of patients with
ER-positive, node-positive tumors. Although the patients
whose tumors overexpressed HER-2/neu seemed to
benefit from adjuvant chemotherapy, an interaction
between HER-2/neu and adjuvant CAF chemotherapy by
statistical analysis could not be demonstrated clearly [6].
Considering all the data available, the use of anthra-
cyclines in HER-2/neu-positive tumors with high expres-
sion was addressed at the NIH consensus meeting in
November 2000. The conclusion of this meeting was not
to consider HER-2/neu as a predictor of response to
anthracyclines [7].
Although some of these studies clearly suggest that
patients whose tumors overexpress HER-2/neu might
benefit from anthracyclines, other studies did not confirm
these findings. One of the main reasons for the discrep-
ancy of these results lies in the tests used in these
studies. Many of the studies were performed by using
immunohistochemistry with different antibodies, some of
which are now considered inaccurate. More recent data
suggest that fluorescence in situ hybridization (FISH)
analysis of the amplified gene is probably the most reliable
and predictable test. The correlation between FISH and
many of the antibodies used is only about 80%. This is
higher than 80% for 3+ protein expression, but is probably
lower for 2+ protein expression. Many of the studies will
therefore have to be reanalyzed for FISH or for more
uniform immunohistochemistry assays. The results are
further confounded by the fact that most of these studies
were retrospective analyses and the randomization was
not stratified for HER-2/neu overexpression.
In summary, it is important to define the value of HER-
2/neu stratification as a predictor of response. So far
there has not been enough evidence to support the use of
anthracyclines in all node-positive patients whose tumors
overexpress HER-2/neu. Nevertheless, anthracycline-
based therapy is effective and showed a small but signifi-
cant increase in disease-free survival as demonstrated by
the Oxford overview in 1998 [8] in the population of node-
positive patients as a whole. Future studies should estab-
lish whether most of the effects of anthracycline-based
chemotherapy are confined to this group.
p53
The p53 tumor suppressor gene is located on the short
arm of chromosome 17. Expression of mutant p53 is the
most common genetic defect in human cancers and
occurs in about 20% of sporadic syndromes, 50% of
familial syndromes and in all cases of Li–Fraumeni syn-
dromes. Mutations in the p53 gene lead to an accumula-
tion of nuclear p53 protein [9].
Functional p53 is required for cell cycle regulation and for
the induction of apoptosis. Preclinical data have shown
that cells with mutated p53 might be resistant to certain
types of apoptotic stimuli such as radiation and
chemotherapeutics [10].
Although in many univariant analyses p53 is associated
with a poor overall survival, this is often not supportedc
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when analyzed as an independent factor. Expression of
mutant  p53 is frequently associated with lack of ER
expression and a high proliferation rate. Furthermore, tech-
nical difficulties and variability in the assays used often
render their assessment difficult.
Several clinical trials have not shown any predictive value
for p53 in women with either node-positive or node-nega-
tive breast cancer receiving CMF [11–15].
The role of p53 as a predictive marker to anthracycline-
based therapy is more complex. Overexpression of p53
conveyed poor response to one perioperative course of 5-
fluorouracil, doxorubicin and cyclophosphamide (FAC) in
women with node-negative breast cancer [16]. However,
this was not seen in women with node-positive breast
cancer treated with three cycles of CAF [4].
In patients treated with epirubicin, mutant p53 predicted
significantly poorer response to neo-adjuvant therapy [15]
and poorer disease-free and overall survival after adjuvant
therapy in patients with node-positive breast cancer [17].
However, although these findings might suggest a role of
p53 as a negative predictor of response to anthracyclines,
more data are needed to confirm these results.
Few studies have focused on the predictive value of p53
and sensitivity to taxane. Preclinical data have suggested
that a loss of p53 confers sensitivity to taxanes [18,19].
However, this has not been supported by clinical studies
and the absence or presence of p53 cannot be used to
determine the need for taxanes in the adjuvant setiing [20].
Bcl-2
Members of the Bcl-2 family are mitochondrial proteins
that regulate programmed cell death. By forming various
homodimers and heterodimers they either promote or
inhibit apoptosis. Bcl-2 inhibits the release of cytochrome
c from the mitochondria and thus prevents the activation
of Apaf-1 and subsequently the caspase pathways [21].
Overexpression of Bcl-2 has been associated with resis-
tance to apoptotic stimuli in several tumors. In breast
cancer, expression of Bcl-2 has been associated with
expression of ER and low proliferation rate; however, it has
not been an independently prognostic factor [22].
Only a few studies are available to assess Bcl-2 as a pre-
dictive factor. The expression of Bcl-2 did not influence
the outcome of perioperative chemotherapy with CAF in
premenopausal patients with lymph-node-negative breast
cancers [23]. In contrast, one study showed that overex-
pression of Bcl-2 was associated with significantly better
overall survival in patients treated with adjuvant CMF [11].
Results from a study in women treated with adjuvant
therapy by using epirubicin and cyclophosphamide
showed that the expression of Bcl-2 was associated with
better disease-free survival and overall survival, but only in
lobular carcinoma, not in ductal carcinoma [17].
The data available are insufficient for definitive conclusions
to be drawn about the role of Bcl-2 as a predictive factor.
Other investigational markers
Of interest are other molecular markers that might be
targets of directed therapy, such as VEGF. Many trials are
evaluating inhibitors of VEGF or VEGF receptor as poten-
tial therapeutic agents. So far no clear correlation between
VEGF expression and response to VEGF inhibitors has
been established. A recent report has suggested that low-
expression VEGF might be an independent predictor for
response to endocrine therapy but not to adjuvant
chemotherapy [24].
Insufficient data are available to suggest a role for cathep-
sin B, Retinoblastoma, p27, PCNA, cyclin D, or Ki-67 as
predictors of response to chemotherapy.
Conclusion
In spite of the fact that many studies have addressed the
use of molecular markers as predictive factors for
chemotherapy, the data remain controversial and inconclu-
sive. Anthracyclines are effective therapy for breast cancer
regardless of HER-2 status, but patients whose tumors
overexpress HER-2 seem to derive the greatest relative
benefit from this therapy. Studies of HER-2 as a predictor
of response to CMF and to radiotherapy are as yet incon-
clusive. On the basis of the currently available data, p53
and Bcl-2 cannot be used to select a specific type of adju-
vant therapy, and insufficient data are available for cathep-
sin B, p27, PCNA, cyclin D, Ki-67 and VEGF.
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